Talampanel for Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, tolerability and safety of oral
administration of talampanel compared to a placebo in subjects with ALS.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries